Display Settings:

Format

Send to:

Choose Destination
Diabetes Res Clin Pract. 2013 Jun;100(3):e78-81. doi: 10.1016/j.diabres.2013.03.011. Epub 2013 Mar 26.

Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.

Author information

  • 1Novartis Pharma AG, Basel, Switzerland. giovanni.bader@novartis.com

Abstract

This post hoc analysis reports that overall proportion of patients achieving a composite endpoint of HbA1c<7.0% (<53.0 mmol/mol) without hypoglycaemia and weight gain was higher with vildagliptin than glimepiride after 2 years in type 2 diabetes patients inadequately controlled on metformin monotherapy, regardless of age and duration of diabetes.

Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

PMID:
23538267
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk